From Financial Modeling Prep: 2025-04-04 02:00:00

In the medical industry, Lifecore Biomedical (NASDAQ:LFCR) reported an EPS of -$0.47 on April 3, 2025, missing the estimated EPS by a significant margin of 35.71%. Revenue was $35.15 million, falling short of the estimated $37.94 million. LFCR has a negative P/E ratio of approximately -4.87 and a strong current ratio of 2.71, showcasing its liquidity position. Despite financial challenges, Lifecore is strategically expanding its business relationships and strengthening its balance sheet by raising funds through the sale of excess capital equipment.



Read more at Financial Modeling Prep:: Lifecore Biomedical, Inc. (NASDAQ:LFCR) Faces Fina…